202 related articles for article (PubMed ID: 28634201)
1. Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes.
Fleuren EDG; Vlenterie M; van der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; van Erp A; van Houdt L; Cebeci SAS; van de Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ
Cancer Res; 2017 Aug; 77(16):4279-4292. PubMed ID: 28634201
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
6. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
7. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
9. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
10. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
11. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib targets in glioblastoma stem cells.
Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
[TBL] [Abstract][Full Text] [Related]
15. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
16. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
[TBL] [Abstract][Full Text] [Related]
18. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.
Imura Y; Nakai T; Yamada S; Outani H; Takenaka S; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
Cancer Sci; 2016 Dec; 107(12):1867-1876. PubMed ID: 27779808
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical relevance of MET and ALK in Ewing sarcomas.
Fleuren ED; Roeffen MH; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
Int J Cancer; 2013 Jul; 133(2):427-36. PubMed ID: 23335077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
